www.nature.com/scientificreports OPEN received: 08 January 2015 accepted: 31 July 2015 Published: 02 September 2015 BA-j as a novel CDK1 inhibitor selectively induces apoptosis in cancer cells by regulating ROS Shixuan Zhang1, Yongming Bao2, Xiulan Ju3, Kangjian Li1, Haiyan ...
Dinaciclib, a CDK1/2/5/9 inhibitor, is currently being evaluated in clinical trials against various cancer types, including BC. However, the underlying molecular mechanisms of CDK1/2/5/9 inhibitors in regulating BC stemness remain poorly understood. The present study aimed to examine the stem...
Indeed, following the success of a pan-CDK inhibitor, palbociclib, in advanced breast cancer, two phase II clinical trials (milciclib and palbociclib) are currently ongoing to evaluate their efficiency on advanced HCC. Unfortunately, milciclib targets CDK2/4/5/7 and palbociclib targets CDK4/6...
NCIC Clinical Trials Group [+1] NCT01627054/Completed临床2期 A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia The purpose of this study is to find out what effects a new drug AT7519M has on chronic lymphocytic leukemia....
[2]. DePinto W, et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther. 2006 Nov;5(11):2644-58. HB220322
The control of glucose metabolism and the cell cycle must be coordinated in order to guarantee sufficient ATP and anabolic substrates at distinct phases of the cell cycle. The family of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFKFB1-4) are
SMALL-MOLECULE INHIBITORCELL-CYCLE PROGRESSIONANDROGEN RECEPTOR PHOSPHORYLATIONELEMENT-BINDING PROTEINPHASE-IMITOTIC PHOSPHORYLATIONDNA-DAMAGESTEM-CELLSCDK1-MEDIATED PHOSPHORYLATIONCyclin dependent kinases (CDKs) are serine/threonine kinases that are proposed as promising candidate targets for cancer treatment. ...
RO-3306 is a selective, ATP-competitive, and cell-permeable CDK1 inhibitor that shows potent anti-tumor activity in multiple pre-clinical models. In this study, we investigated the effect of CDK1 expression on the prognosis of patients with ovarian cancer and the anti-tumorigenic effect of RO...
RO-3306 is a selective, ATP-competitive, and cell-permeable CDK1 inhibitor that shows potent anti-tumor activity in multiple pre-clinical models. In this study, we investigated the effect of CDK1 expression on the prognosis of patients with ovarian cancer and the anti-tumorigenic effect of RO...
pan-CDK inhibitor, in patients with advanced solid tumors182. Furthermore, several clinical trials of CDK1 associated inhibitors combining with other anti-cancer agents are ongoing to evaluate the combination treatment in cancer (NCT03579836; NCT03484520; NCT01434316; NCT01676753). These clinical ...